Antibodies against IL-17BR
The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.
1. A method for the treatment or reduction of inflammatory bowel disease, said method comprising administering to a subject in need thereof an effective amount of an antibody molecule which binds IL-17BR and which comprises
an antibody VH domain comprising a CDR1 having an amino acid sequence as set out in SEQ ID NO:5, a CDR2 having an amino acid sequence as set out in SEQ ID NO:6, and a CDR3 having an amino acid sequence as set out in SEQ ID NO:7, and
an antibody VL domain with a CDR1 having an amino acid sequence as set out in SEQ ID NO:8, a CDR2 having an amino acid sequence as set out in SEQ ID NO:9, and a CDR3 having an amino acid sequence as set out in SEQ ID NO:10,
optionally in a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
3. The method of claim 1 , wherein the VH domain comprises a human framework region.
4. The method of claim 1 , wherein the VH domain comprises SEQ ID NO:2.
5. The method of claim 1 , wherein the VL domain comprises a human framework region.
6. The method of claim 1 , wherein the VL domain comprises SEQ ID NO: 4.
7. The method of claim 1 , wherein the antibody molecule is a Fab, F(ab′) 2 , or single chain variable fragment (scFv) antibody fragment.
8. The method of claim 1 , wherein the antibody molecule comprises an antibody constant region.
9. The method of claim 8 , wherein the constant region is an IgG1 or IgG4 constant region.
10. The method of claim 8 , wherein the antibody molecule comprises a whole antibody.